AURORA, ON--(Marketwire - February 9, 2011) - Helix BioPharma Corp. (
Dr. Chao is an invited speaker and will be presenting at 11:40am (Gulf Standard Time), an overview of Helix BioPharma's lung cancer drug candidate, L-DOS47. The presentation will highlight the preclinical work leading up to the recent United States Food and Drug Administration ("FDA") approval of a Phase I investigational new drug ("IND") application to commence human clinical testing with L-DOS47. Later that day, 2:50pm - 4:15pm GST, Dr. Chao will conduct a poster presentation providing an overview of Helix BioPharma's Topical Interferon Alpha-2b program. Both the slide show portion of the L-DOS47 presentation and the poster on Topical Interferon Alpha-2b will be available on Helix BioPharma's website (www.helixbiopharma.com).
Additional information about the conference, provided by the organizers, can be found at the conference's website http://www.icddt.com/index.htm.
About L-DOS47
L-DOS47 is the Company's first drug candidate under development based upon its DOS47 technology. L-DOS47 is a therapeutic immunoconjugate which combines Helix's proprietary DOS47 technology with a highly specialized camelid-derived single domain antibody designed to identify a unique CEACAM6 antigenic site predominantly associated with non-small cell lung cancer ("NSCLC") cells. DOS47 is designed to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By breaking down urea at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.
About Topical Interferon Alpha-2b
Interferon alpha-2b is a potent cytokine that possesses antiviral, immunomodulatory and antiproliferative activities with activity against HPV. Topical Interferon Alpha-2b is a semi-solid formulation of recombinant interferon alpha-2b based on Helix's Biphasix™ platform drug formulation technology. This technology involves the formation of biphasic lipid vesicles for use as a vehicle for administration of a biologically active material encapsulated within the lipid bilayers. Topical Interferon Alpha-2b is under development as a cosmetically appealing cream dosage form that can be easily and conveniently self-applied intravaginally for the treatment of low-grade cervical lesions using a common vaginal applicator.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX, NYSE Amex and FSE under the symbol "HBP". For more information, please visit www.helixbiopharma.com.
Forward-Looking Statements and Risks and Uncertainties
This News Release contains certain forward-looking statements and information (collectively, "forward-looking statements"), regarding the Company's planned presentation at the Third International Conference on Drug Discovery and Therapy being held in Dubai UAE and the Company's product development initiatives. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions which have been applied in making forward-looking statements, include, but are not limited to, assumptions regarding the Company's attendance at the conference; the safety and efficacy of Helix's drug candidates; the timely receipt of necessary regulatory approvals and appropriate financing; and that the Company's drug candidates will ultimately be successfully developed and commercialized. These forward-looking statements are subject to risks and uncertainties that may cause actual events or results to differ materially from such statements. These risks and uncertainties include without limitation, that the Company's assumptions may prove to be incorrect; that the presentation is subject to change or cancellation without notice; Helix's need for additional future capital, which may not be available; uncertainty whether the drug candidates will be successfully developed and commercialized; research and development risks, including manufacturing risks and negative clinical trial results; product liability and insurance risks; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; and uncertainty of the size and existence of a market opportunity for Helix's products. These and other risks and uncertainties, which could cause actual results to vary materially from current results or those anticipated in forward-looking statements, are more fully described in our latest Form 20-F and other documents filed on SEDAR at www.sedar.com and on EDGAR at ww.sec.gov. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact Information:
For further information contact:
Investor Relations:
Stanley Wunderlich
Consulting for Strategic Growth 1 Ltd.
Tel: 800-625-2236 ext. 7770
Email:
Web Site: www.sternco.com